FMP

FMP

Enter

AUPH - Aurinia Pharmaceutic...

photo-url-https://images.financialmodelingprep.com/symbol/AUPH.png

Aurinia Pharmaceuticals Inc.

AUPH

NASDAQ

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

8.93 USD

0.05 (0.56%)

About

ceo

Mr. Peter S. Greenleaf M.B.A.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

CIK

0001600620

ISIN

CA05156V1022

CUSIP

05156V102

Address

4464 Markham Street

Phone

12507084272

Country

CA

Employee

300

IPO Date

Sep 3, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep